From: Endothelial function in migraine: a cross-sectional study
Control subjects (n = 16) | Migraine patients (n = 16) | |||||||
---|---|---|---|---|---|---|---|---|
Sodium nitroprusside dose, μg.min-1.dL-1 forearm | 0 | 0.2 | 0.4 | 0.8 | 0 | 0.2 | 0.4 | 0.8 |
non-infused arm | 2.0 ± 0.9 | 1.9 ± 0.7 | 1.8 ± 0.8 | 1.8 ± 0.8 | 2.0 ± 0.5 | 2.0 ± 0.6 | 2.1 ± 0.8 | 1.9 ± 0.6 |
infused arm | 2.0 ± 0.5 | 8.6 ± 3.5 | 10.9 ± 4.2 | 14.5 ± 5.9* | 2.1 ± 0.5 | 8.7 ± 2.9 | 12.1 ± 4.6 | 16.5 ± 6.2* |
Substance P dose, pmol.min-1.dL-1 forearm | 0 | 0.2 | 0.4 | 0.8 | 0 | 0.2 | 0.4 | 0.8 |
non-infused arm | 1.8 ± 0.8 | 1.8 ± 0.7 | 1.8 ± 0.7 | 1.9 ± 0.8 | 2.0 ± 0.6 | 1.9 ± 0.6 | 2.1 ± 0.6 | 2.0 ± 0.6 |
infused arm | 2.2 ± 0.7 | 5.5 ± 2.2 | 6.9 ± 2.5 | 8.7 ± 3.8* | 2.5 ± 0.7 | 5.1 ± 1.2 | 6.5 ± 1.8 | 8.4 ± 2.5* |
L-NMMA dose, μmol.min-1.dL-1 forearm | 0 | 0.1 | 0.2 | 0.4 | 0 | 0.1 | 0.2 | 0.4 |
non-infused arm | 1.7 ± 0.5 | 1.8 ± 0.7 | 1.9 ± 0.9 | 1.9 ± 0.8 | 2.1 ± 0.5 | 1.9 ± 0.6 | 2.1 ± 0.6 | 2.4 ± 0.8 |
infused arm | 2.0 ± 0.5 | 1.7 ± 0.4 | 1.6 ± 0.4 | 1.4 ± 0.4* | 2.5 ± 0.6 | 2.0 ± 0.5 | 1.9 ± 0.6 | 1.9 ± 0.6* |